Fight for Sight has announced funding for vital research that could help save the sight of children with retinoblastoma.
News
RCGP calls for better access to cancer diagnostic tests
GP access to appropriate diagnostic tests in the community is currently amongst the lowest in Europe, a report by The Health Foundation has found.
The King’s Fund reports life expectancy has ‘ground to a halt’
A report published by The King’s Fund has found that improvements in life expectancy have “ground to a halt”.
EU green light for Takeda’s Alunbrig
Takeda’s Alunbrig has been approved in Europe as a treatment for a specific group of lung cancer patients, but access to the drug in the UK remains uncertain.
US approves first ever TRK inhibitor
Bayer and Loxo Oncology’s Vitrakvi has become the first ever TRK inhibitor to be approved in the US, having been cleared to treat advanced solid tumours harbouring an NTRK gene fusion.
First children set to receive Novartis’ Kymriah
The first children to receive Novartis’ Kymriah – a ‘game-changing’ CAR-T therapy for cancer – will start treatment at Great Ormond Street Hospital in London this week, NHS England has announced.
Join the medical & scientific community at the MSEA awards 2018
The first edition of the PharmaTimes Medical & Scientific Excellence Awards will take place on Thursday 6th December – the competition will take place during the day, with the dinner and awards ceremony following in the evening at The Sofitel Hotel, Gatwick.
US grants AZ’ Fasenra orphan drug status for rare autoimmune disease
US regulators have granted AstraZeneca’s Fasenra Orphan Drug Designation for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare and potentially fatal autoimmune disease.
Poteligeo approved in Europe for Mycosis Fungoides, Sézary Syndrome
Kyowa Hakko Kirin (Kyowa Kirin) has received marketing authorisation Europe for use of Poteligeo to treat Mycosis Fungoides and Sézary Syndrome.
Royal College of GPs backs ‘People’s Vote’ on Brexit
The Royal College of General Practitioners’ governing Council has passed a motion in support of a second referendum – commonly known as a ‘People’s Vote’ – on Brexit negotiations.
NHS set to save record £300 million on highest drug spend
The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug.
EU OKs Mundipharma’s Neulasta biosimilar
The Mundipharma network of independent associated companies says European regulators have approved use of Pelmeg, a biosimilar of Amgen’s white blood cell booster Neulasta.
Vectura pulls the plug on experimental asthma therapy
Vectura says it no longer plans to develop and partner experimental asthma therapy VR475, after it failed to hit Phase III targets.
Generation Z expect ‘technology revolution’ in the NHS
New research from Roche UK has revealed that 82% of Generation Z, the age group encompassing 16 to 24 year olds, want to see the NHS introduce digital solutions to better manage their health and improve care.
Cell and Gene Therapy Catapult addresses sector skills gap
The Cell and Gene Therapy (CGT) Catapult has launched the first Advanced Therapy Medicinal Products (ATMP) focused apprenticeship programme, developed in partnership with The Medicine Manufacturing Industry Partnership (MMIP).
